Biocryst Pharmaceuticals INC 8-K filings

BioCryst Pharmaceuticals announced robust second quarter 2026 financial results, including increased total revenue guidance and positive free cash flow, alongside significant pipeline advancements.

BioCryst Pharmaceuticals provides updated cost estimates for its plan to discontinue internal discovery programs and close its Birmingham facility.

BioCryst Pharmaceuticals announced a strategic shift to discontinue internal discovery programs and close its Birmingham, Alabama facility by year-end 2026, focusing on external innovation and reaffirming revenue guidance while lowering operating expense projections.

BioCryst Pharmaceuticals stockholders approved an amendment to the company's Stock Incentive Plan, authorizing an additional 7,000,000 shares for issuance.

BioCryst Pharmaceuticals announced first quarter 2026 financial results, highlighting strong ORLADEYO revenue growth and a significant licensing agreement for navenibart in Europe.

BioCryst Pharmaceuticals has entered into a licensing agreement with an Irish affiliate of Neopharmed Gentili S.p.A. for the commercialization of navenibart in Europe, securing $70 million upfront and potential future payments.

BioCryst Pharmaceuticals reported record full-year 2025 financial results, achieving profitability for the first time, driven by strong ORLADEYO sales and strategic business developments.

BioCryst Pharmaceuticals, Inc. announced the completion of its merger with Astria Therapeutics, Inc. and the appointment of Dr. Jill C. Milne to its Compensation and Science Committees.

BioCryst Pharmaceuticals has finalized its acquisition of Astria Therapeutics, integrating a late-stage hereditary angioedema therapy and expanding its rare disease leadership.

BioCryst Pharmaceuticals announced preliminary 2025 ORLADEYO net revenue surpassed guidance and provided strong 2026 financial projections, including the impact of the Astria Therapeutics acquisition.

BioCryst Pharmaceuticals announced an increase in the wholesale acquisition cost for its drug ORLADEYO in the United States, effective January 9, 2026.

BioCryst Pharmaceuticals receives FDA approval for its ORLADEYO oral pellet formulation, expanding its use to pediatric patients aged 2 to less than 12 years with hereditary angioedema.

BioCryst Pharmaceuticals, Inc. announced the retirement of its Board Chair, Dr. Nancy J. Hutson, and the election of Vincent J. Milano as her successor.

BioCryst Pharmaceuticals receives early HSR termination, advancing its proposed acquisition of Astria Therapeutics towards a Q1 2026 close.

BioCryst Pharmaceuticals reported strong third-quarter 2025 financial results driven by ORLADEYO sales, raised full-year guidance, completed its European business sale to retire debt, and announced the acquisition of Astria Therapeutics.

BioCryst Pharmaceuticals announced a definitive agreement to acquire Astria Therapeutics for approximately $920 million in equity value, strengthening its hereditary angioedema (HAE) portfolio with late-stage asset navenibart.

BioCryst Pharmaceuticals completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million upfront, enhancing focus on the U.S. market and improving operating margins.

BioCryst Pharmaceuticals announces the resignation of its Chief Research and Development Officer, Dr. Helen Thackray, effective September 1, 2025.

BioCryst Pharmaceuticals announced record second quarter 2025 financial results, driven by robust ORLADEYO revenue growth and significant operating profit, alongside strategic debt reduction plans.

BioCryst Pharmaceuticals announces a planned leadership transition with Chief Commercial Officer Charlie Gayer succeeding Jon Stonehouse as President and CEO, effective in phases through early 2026.

BioCryst Pharmaceuticals, Inc. announced the appointment of Babar Ghias, a seasoned financial and corporate development executive with extensive experience in rare diseases and capital raising, as its new Chief Financial Officer and Head of Corporate Development, effective July 7, 2025.

BioCryst Pharmaceuticals, Inc. has entered into a definitive agreement to sell its European ORLADEYO business to Neopharmed Gentili S.p.A. for an upfront cash payment of $250 million and up to $14 million in future revenue milestones.

BioCryst Pharmaceuticals, Inc. announced the sale of its European ORLADEYO business to Neopharmed Gentili for up to $264 million, with proceeds primarily used to retire all remaining term debt and significantly boost future cash reserves.

BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its new drug application (NDA) for ORLADEYO in pediatric hereditary angioedema (HAE) patients.

BioCryst Pharmaceuticals, Inc. announced the retirement of long-serving director George B. Abercrombie and secured stockholder approval for an amended stock incentive plan, significantly increasing the pool of shares available for equity awards.

BioCryst Pharmaceuticals, Inc. announced the extension of a consulting agreement with former Chief Financial Officer Anthony Doyle through December 31, 2025, to ensure continuity during the CFO transition process.

BioCryst Pharmaceuticals announces FDA acceptance and priority review for ORLADEYO in pediatric HAE patients, with a PDUFA target action date of September 12, 2025.

BioCryst Pharmaceuticals reports strong Q1 2025 results, driven by ORLADEYO sales, leading to increased revenue guidance and accelerated profitability expectations.

BioCryst Pharmaceuticals expands its board of directors with the appointment of healthcare investment banking leader Steve Frank, effective May 2, 2025.

BioCryst Pharmaceuticals announces the departure of its CFO, Anthony Doyle, and the appointment of Jon P. Stonehouse as Interim CFO, effective April 9, 2025.